Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 8—August 2022
CME ACTIVITY - Synopsis

Lack of Evidence for Ribavirin Treatment of Lassa Fever in Systematic Review of Published and Unpublished Studies1

Hung-Yuan Cheng, Clare E. French, Alex P. Salam, Sarah Dawson, Alexandra McAleenan, Luke A. McGuinness, Jelena Savović, Peter W. Horby, and Jonathan A.C. SterneComments to Author 
Author affiliations: Population Health Sciences, University of Bristol, Bristol, UK (H.-Y. Cheng, C.E. French, S. Dawson, A. McAleenan, L.A. McGuinness, J. Savović, J.A.C. Sterne); National Institute for Health and Care Research (NIHR) Health Protection Research Unit in Behavioural Science and Evaluation, University of Bristol, Bristol (C.E. French); United Kingdom Public Health Rapid Support Team, London, UK (A.P. Salam); Pandemic Sciences Centre, University of Oxford, Oxford, UK (A.P. Salam, P.W. Horby); NIHR Applied Research Collaboration West, Bristol (J. Savović); International Severe Acute Respiratory and Emerging Infections Consortium, Oxford (P. Horby); NIHR Bristol Biomedical Research Centre, Bristol (J.A.C. Sterne); Health Data Research UK South West, Bristol (J.A.C. Sterne)

Main Article

Figure 3

Estimated effects of ribavirin compared with no treatment on mortality outcomes from the McCormick (11) and IND 16666 (Birch & Davis Associates and Sherikon Inc., US Army Medical Research and Development Command, unpub. data, https://media.tghn.org/medialibrary/2019/03/Responsive_Documents_of_Peter_Horby.pdf.pdf; G.V. Ludwig, pers. comm., 2019 March 4, https://media.tghn.org/medialibrary/2019/03/Dr._Ludwig_memo.pdf) studies in a systematic review of published and unpublished studies for evidence for ribavirin treatment of Lassa fever. A horizontal line represents the 95% CI of a study result, with each end of the line representing the boundaries. A point estimate of the study result is represented by a black diamond. A gray box gives a representation of the size of a study compared with all studies in the figure.

Figure 3. Estimated effects of ribavirin compared with no treatment on mortality outcomes from the McCormick (11) and IND 16666 (Birch & Davis Associates and Sherikon Inc., US Army Medical Research and Development Command, unpub. data, https://media.tghn.org/medialibrary/2019/03/Responsive_Documents_of_Peter_Horby.pdf.pdf; G.V. Ludwig, pers. comm., 2019 March 4, https://media.tghn.org/medialibrary/2019/03/Dr._Ludwig_memo.pdf) studies in a systematic review of published and unpublished studies for evidence for ribavirin treatment of Lassa fever. A horizontal line represents the 95% CI of a study result, with each end of the line representing the boundaries. A point estimate of the study result is represented by a black diamond. A gray box gives a representation of the size of a study compared with all studies in the figure.

Main Article

References
  1. Frame  JD, Baldwin  JM Jr, Gocke  DJ, Troup  JM. Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings. Am J Trop Med Hyg. 1970;19:670–6. DOIPubMedGoogle Scholar
  2. Ogbu  O, Ajuluchukwu  E, Uneke  CJ. Lassa fever in West African sub-region: an overview. J Vector Borne Dis. 2007;44:1–11.PubMedGoogle Scholar
  3. McCormick  JB, Fisher-Hoch  SP. Lassa fever. Curr Top Microbiol Immunol. 2002;262:75–109. DOIPubMedGoogle Scholar
  4. World Health Organization. Lassa fever. 2021 [cited 2022 Mar 22]. https://www.who.int/health-topics/lassa-fever
  5. McCormick  JB, King  IJ, Webb  PA, Johnson  KM, O’Sullivan  R, Smith  ES, et al. A case-control study of the clinical diagnosis and course of Lassa fever. J Infect Dis. 1987;155:445–55. DOIPubMedGoogle Scholar
  6. McCormick  JB, Webb  PA, Krebs  JW, Johnson  KM, Smith  ES. A prospective study of the epidemiology and ecology of Lassa fever. J Infect Dis. 1987;155:437–44. DOIPubMedGoogle Scholar
  7. Fisher-Hoch  SP, Tomori  O, Nasidi  A, Perez-Oronoz  GI, Fakile  Y, Hutwagner  L, et al. Review of cases of nosocomial Lassa fever in Nigeria: the high price of poor medical practice. BMJ. 1995;311:857–9. DOIPubMedGoogle Scholar
  8. Fisher-Hoch  SP, McCormick  JB, Auperin  D, Brown  BG, Castor  M, Perez  G, et al. Protection of rhesus monkeys from fatal Lassa fever by vaccination with a recombinant vaccinia virus containing the Lassa virus glycoprotein gene. Proc Natl Acad Sci U S A. 1989;86:317–21. DOIPubMedGoogle Scholar
  9. Lukashevich  IS, Carrion  R Jr, Salvato  MS, Mansfield  K, Brasky  K, Zapata  J, et al. Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates. Vaccine. 2008;26:5246–54. DOIPubMedGoogle Scholar
  10. CEPI Press Office. CEPI partner INOVIO launches Lassa vaccine phase I trial in West Africa. 2021 Feb 23 [cited 2022 Mar 22]. https://cepi.net/news_cepi/cepi-partner-inovio-launches-lassa-vaccine-phase-i-trial-in-west-africa
  11. McCormick  JB, King  IJ, Webb  PA, Scribner  CL, Craven  RB, Johnson  KM, et al. Lassa fever. Effective therapy with ribavirin. N Engl J Med. 1986;314:20–6. DOIPubMedGoogle Scholar
  12. Shaffer  JG, Grant  DS, Schieffelin  JS, Boisen  ML, Goba  A, Hartnett  JN, et al.; Viral Hemorrhagic Fever Consortium. Lassa fever in post-conflict sierra leone. PLoS Negl Trop Dis. 2014;8:e2748. DOIPubMedGoogle Scholar
  13. Okokhere  P, Colubri  A, Azubike  C, Iruolagbe  C, Osazuwa  O, Tabrizi  S, et al. Clinical and laboratory predictors of Lassa fever outcome in a dedicated treatment facility in Nigeria: a retrospective, observational cohort study. Lancet Infect Dis. 2018;18:684–95. DOIPubMedGoogle Scholar
  14. Dahmane  A, van Griensven  J, Van Herp  M, Van den Bergh  R, Nzomukunda  Y, Prior  J, et al. Constraints in the diagnosis and treatment of Lassa Fever and the effect on mortality in hospitalized children and women with obstetric conditions in a rural district hospital in Sierra Leone. Trans R Soc Trop Med Hyg. 2014;108:126–32. DOIPubMedGoogle Scholar
  15. Shaffer  JG, Schieffelin  JS, Grant  DS, Goba  A, Momoh  M, Kanneh  L, et al.; Viral Hemorrhagic Fever Consortium. Data set on Lassa fever in post-conflict Sierra Leone. Data Brief. 2019;23:103673. DOIPubMedGoogle Scholar
  16. Inegbenebor  U, Okosun  J, Inegbenebor  J. Prevention of lassa Fever in Nigeria. Trans R Soc Trop Med Hyg. 2010;104:51–4. DOIPubMedGoogle Scholar
  17. Ajayi  NA, Nwigwe  CG, Azuogu  BN, Onyire  BN, Nwonwu  EU, Ogbonnaya  LU, et al. Containing a Lassa fever epidemic in a resource-limited setting: outbreak description and lessons learned from Abakaliki, Nigeria (January-March 2012). Int J Infect Dis. 2013;17:e1011–6. DOIPubMedGoogle Scholar
  18. Salam  AP, Cheng  V, Edwards  T, Olliaro  P, Sterne  J, Horby  P. Time to reconsider the role of ribavirin in Lassa fever. PLoS Negl Trop Dis. 2021;15:e0009522. DOIPubMedGoogle Scholar
  19. Sterne  JA, Hernán  MA, Reeves  BC, Savović  J, Berkman  ND, Viswanathan  M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. DOIPubMedGoogle Scholar
  20. Moher  D, Liberati  A, Tetzlaff  J, Altman  DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339(jul21 1):b2535.
  21. Ouzzani  M, Hammady  H, Fedorowicz  Z, Elmagarmid  A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5:210. DOIPubMedGoogle Scholar
  22. Hernán  MA, Sauer  BC, Hernández-Díaz  S, Platt  R, Shrier  I. Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. J Clin Epidemiol. 2016;79:70–5. DOIPubMedGoogle Scholar
  23. Hamblion  EL, Raftery  P, Wendland  A, Dweh  E, Williams  GS, George  RNC, et al. The challenges of detecting and responding to a Lassa fever outbreak in an Ebola-affected setting. Int J Infect Dis. 2018;66:65–73. DOIPubMedGoogle Scholar
  24. Allan  R, Mardell  S, Ladbury  R, Pearce  E, Skinner  K, Saluzzo  JF, et al. The progression from endemic to epidemic Lassa fever in war-torn West Africa. In: Saluzzo JF, Dodet B, editors. Emergence and control of rodent-borne viral diseases: hantaviral and arenal diseases: congrès, Annecy, 28–31 Octobre 1998. 1st edition. Paris: Elsevier; 1999. p. 197–205.
  25. Ehichioya  D, Asogun  D, Hass  M, Becker-Ziaja  B, Gunther  S, Omilabu  S. A retrospective laboratory analysis of clinically diagnosed Lassa fever cases in a tertiary hospital in Nigeria. Int J Infect Dis. 2010;1:e209–10. DOIGoogle Scholar
  26. Fisher-Hoch  SP, Gborie  S, Parker  L, Huggins  J. Unexpected adverse reactions during a clinical trial in rural west Africa. Antiviral Res. 1992;19:139–47. DOIPubMedGoogle Scholar
  27. Riner  A, Chan-Tack  KM, Murray  JS. Original research: Intravenous ribavirin—review of the FDA’s Emergency Investigational New Drug Database (1997-2008) and literature review. Postgrad Med. 2009;121:139–46. DOIPubMedGoogle Scholar
  28. Ilesanmi  O, Ayodeji  O, Abejegah  C. Mortality among confirmed Lassa fever cases during the 2017–2019 outbreak in Ondo State, Nigeria [abstract]. Trans R Soc Trop Med Hyg. 2019;113(Suppl 1):S89.
  29. Asogun  DA, Adomeh  DI, Ehimuan  J, Odia  I, Hass  M, Gabriel  M, et al. Molecular diagnostics for lassa fever at Irrua specialist teaching hospital, Nigeria: lessons learnt from two years of laboratory operation. PLoS Negl Trop Dis. 2012;6:e1839. DOIPubMedGoogle Scholar
  30. Bouree  P. Les parasitoses intestinales sont encore fréquentes. Med Sante Trop. 2015;25:130. DOIGoogle Scholar
  31. Buba  MI, Dalhat  MM, Nguku  PM, Waziri  N, Mohammad  JO, Bomoi  IM, et al. Mortality among confirmed Lassa fever cases during the 2015–2016 outbreak in Nigeria. Am J Public Health. 2018;108:262–4. DOIPubMedGoogle Scholar
  32. Ilori  EA, Furuse  Y, Ipadeola  OB, Dan-Nwafor  CC, Abubakar  A, Womi-Eteng  OE, et al.; Nigeria Lassa Fever National Response Team. Epidemiologic and clinical features of Lassa fever outbreak in Nigeria, January 1–May 6, 2018. Emerg Infect Dis. 2019;25:1066–74. DOIPubMedGoogle Scholar
  33. Joseph  A, Robinson  O, Justus  E, Matthew  N, Chukwuemeka  U. Clinical profile of Lassa fever patients in Abakaliki, south-eastern Nigeria, January–March 2018. Ann Med Health Sci Res. 2019;9:598–602.
  34. Price  ME, Fisher-Hoch  SP, Craven  RB, McCormick  JB. A prospective study of maternal and fetal outcome in acute Lassa fever infection during pregnancy. BMJ. 1988;297:584–7. DOIPubMedGoogle Scholar
  35. Samuels  RJ, Moon  TD, Starnes  JR, Alhasan  F, Gbakie  M, Goba  A, et al. Lassa fever among children in Eastern Province, Sierra Leone: a 7-year retrospective analysis (2012–2018). Am J Trop Med Hyg. 2020;104:585–92. DOIPubMedGoogle Scholar
  36. Wauquier  N, Couffignal  C, Manchon  P, Smith  E, Lungay  V, Coomber  M, et al. High heart rate at admission as a predictive factor of mortality in hospitalized patients with Lassa fever: An observational cohort study in Sierra Leone. J Infect. 2020;80:671–93. DOIPubMedGoogle Scholar
  37. Bausch  DG, Hadi  CM, Khan  SH, Lertora  JJ. Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever. Clin Infect Dis. 2010;51:1435–41. DOIPubMedGoogle Scholar
  38. World Health Organization. Clinical management of patients with viral haemorrhagic fever: a pocket guide for front-line health workers: inerim emergency guidance for country adaptation. 2016 Feb [cited 2022 Mar 22]. https://apps.who.int/iris/bitstream/handle/10665/205570/9789241549608_eng.pdf
  39. World Health Organization. WHO R&D blueprint. “Efficacy trials of Lassa therapeutics: endpoints, trial design, site selection” WHO workshop—final report. 2018 Apr 25 [cited 2022 Mar 22]. https://www.who.int/blueprint/what/norms-standards/LassaTxeval_FinalmeetingReport.pdf
  40. Raabe  VN, Kann  G, Ribner  BS, Morales  A, Varkey  JB, Mehta  AK, et al.; Emory Serious Communicable Diseases Unit. Favipiravir and ribavirin treatment of epidemiologically linked cases of Lassa fever. Clin Infect Dis. 2017;65:855–9. DOIPubMedGoogle Scholar
  41. Eberhardt  KA, Mischlinger  J, Jordan  S, Groger  M, Günther  S, Ramharter  M. Ribavirin for the treatment of Lassa fever: A systematic review and meta-analysis. Int J Infect Dis. 2019;87:15–20. DOIPubMedGoogle Scholar

Main Article

1Preliminary results from this study were presented at the World Health Organization Emergency Program on December 21, 2019.

Page created: June 14, 2022
Page updated: July 24, 2022
Page reviewed: July 24, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external